


VALUATION MULTIPLES

Forward EV / EBITDA Multiples (monthly to 31/12/2018) Source: FactSet Research Systems Inc.

Multiples in the Healthcare sector have slightly increased over the period. At the end of December, the sector traded on a forward EV / EBITDA multiple of 10.3x, compared to the ASX200 on 8.9x.



Average Values and Trading Multiples (values as at 18/01/2019) Source: FactSet Research Systems Inc.

Subsector	Enterprise Value (\$ m)	EV/EBITDA FY2019	EV/EBIT FY2019	Price / Earnings FY2019
Aged Care	2,437	8.6x	11.7x	14.5x
Animal Health	1,182	8.2x	10.5x	13.5x
Biotech	92,905	22.5x	25.5x	32.3x
Hospitals & Clinics	38,237	9.5x	13.1x	16.6x
Medical Devices	10,659	25.6x	28.1x	38.7x
Healthcare	146,409	10.5x	13.5x	17.3x

Note: Multiples are based on the forward year of the unreported period, which for the majority of companies in the sector is FY2019. Difference in forward EV/EBITDA multiples between Figure and Table are representative of the timing difference between month-end result, and current day result.

¹ The InterFinancial Healthcare Index set is an unweighted index comprising Healthcare sector related companies trading on the Australian Securities Exchange (ASX). Estimates are sourced from FactSet Research Systems Inc.

MERGER & ACQUISITION NEWS...

CAPITOLHEALTH
LIMITED



Value: \$8.1m

Capitol Health announced the acquisition of four clinics in metropolitan Melbourne from **Uniradiology**. The aggregate acquisition consideration is \$8.1m upfront on a cash and debt free basis (plus the assumption of transferring employee entitlements).

UNDER THE MICROSCOPE...

- **Healius'** second largest institutional shareholder **Harris Associates** says that China's **JanghoGroup** will need to significantly increase its \$2bn takeover offer. **Jangho's** offer of \$3.25 per share was too low to justify providing access to due diligence and **Healius'** board made the right decision when it rejected the conditional proposal. Sources said that both sides decided that it would be in their best interest to continue discussions.
 - **Tap into Safety**, a private Australian physical and mental health software developer, would consider a trade sale in 12-18 months after the 2019 global roll-out of its new Software-as-a-Service (SaaS) platform. Now valued at around \$8m, compared with 2017's \$5m, the company is closer to a potential exit, and is happy to start engaging with interested parties or advisors.
 - **Westpac** and **National Australia Bank** are financing **Australian Pharmaceutical Industries'** \$727m takeover offer for **Sigma Healthcare**. The deal will be funded entirely using debt.
-

CONTACT DETAILS

If you are interested in specific information regarding mergers and acquisitions in the Healthcare sector, please contact Yvonne Macleod or Michael Kakanis.

Name	Position	Phone	Email
Sharon Doyle	Managing Director	(07) 3218 9122	sdoyle@interfinancial.com.au
Paul Keehan	Chairman	(07) 3218 9100	pkeehan@interfinancial.com.au
Mark Steinhardt	Head of M&A	(07) 3218 9105	msteinhardt@interfinancial.com.au
Cathy Montesin	Director	(07) 3218 9100	cmontesin@interfinancial.com.au
David Hassum	Director	(07) 3218 9108	dhassum@interfinancial.com.au
Andrew Wheeler	Director	(07) 3218 9107	awheeler@interfinancial.com.au
Simon Douglas	Director	(07) 3218 9100	sdouglas@interfinancial.com.au
Ted Marchant	Director	(07) 3218 9100	tmarchant@interfinancial.com.au
Yvonne Macleod	Director	(07) 3218 9100	ymacleod@interfinancial.com.au
Brad Shaw	Director	(07) 3218 9100	bshaw@interfinancial.com.au
Anthony Vago	Associate Director	(07) 3218 9100	avago@interfinancial.com.au
Tom Benham	Associate Director	(07) 3218 9113	tbenham@interfinancial.com.au
Erik Padding	Associate	(07) 3218 9112	epadding@interfinancial.com.au
Michael Kakanis	Associate	(07) 3218 9106	mkakanis@interfinancial.com.au

DISCLAIMER

This information has been sourced from the ASX, Mergermarket.com and various other public information sources. Forecasts are consensus forecasts sourced from FactSet Research Systems Inc.

Important Disclaimer – This may affect your legal rights: Because this document has been prepared without consideration of any specific person's financial situation, particular needs and investment objectives, a financial services licensee or investment adviser should be consulted before any investment decision is made. While this document is based on information from sources which are considered reliable, InterFinancial, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does InterFinancial accept any responsibility to inform you of any matter that subsequently comes to notice, which may affect any of the information contained in this document. This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of InterFinancial. This report does not constitute advice to any person.

Disclosure. InterFinancial has no interest in any of the securities mentioned in this publication. However, its directors, executives or consultants may have an interest in some of the securities, directly or indirectly, which are mentioned.

InterFinancial is a member of Clairfield International, an international corporate finance firm that provides advisory services in crossborder mergers and acquisitions. Clairfield is represented by over 400 people across 22 countries, closing over 100 transactions each year.

InterFinancial
Corporate Finance Limited
ABN: 49 136 962 966
AFSL: 341675
Level 2, 201 Charlotte Street
GPO Box 975
Brisbane Queensland 4001
(07) 3218 9100
admin@interfinancial.com.au
www.interfinancial.com.au

